Eris Lifesciences' consolidated net profit rose 4% to Rs 56.06 crore on 15.6% jump in net sales to Rs 244.09 crore in Q4 March 2020 over Q4 March 2019.
Consolidated profit before tax gained 5.9% to Rs 61.67 crore in Q4 March 2020 as against Rs 58.24 crore in Q4 March 2019. Current tax expenses dropped 11.3% to Rs 11.76 crore in Q4 March 2020 as against Rs 13.26 crore in Q4 March 2019. The Q4 result was declared during trading hours today, 2 June 2020.
Eris Lifesciences, in its exchange filing, also assured that it will continue to monitor the COVID-19 impact on its business which majorly entails its supply-chain and customers.
Eris Lifesciences is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian pharmaceutical market.
Shares of Eris Lifesciences declined 2% to Rs 517.65 on BSE. The scrip hovered in the range of Rs 501.50 to Rs 593.40 so far.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
